MorphoSys AG (ETR:MOR - Get Free Report) dropped 0.1% during trading on Wednesday . The company traded as low as €66.50 ($71.51) and last traded at €66.75 ($71.77). Approximately 106,985 shares traded hands during mid-day trading, a decline of 30% from the average daily volume of 153,687 shares. The stock had previously closed at €66.80 ($71.83).
MorphoSys Stock Performance
The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of -12.07, a price-to-earnings-growth ratio of 0.06 and a beta of 0.60. The company has a current ratio of 3.08, a quick ratio of 3.49 and a debt-to-equity ratio of 3,454.18. The firm has a 50-day simple moving average of €66.73 and a two-hundred day simple moving average of €47.35.
About MorphoSys
(
Get Free Report)
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MorphoSys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MorphoSys wasn't on the list.
While MorphoSys currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
